Scalper1 News
Beleaguered big biotech Biogen (BIIB) beat Q3 estimates and raised guidance Wednesday morning while announcing a round of layoffs and the failure of a multiple-sclerosis drug trial. Biogen stock rose as much as 9.5% in early trading. Biogen made $4.48 a share in the quarter, excluding one-time items, up 18% from the year-earlier quarter and beating analysts’ consensus by 68 cents, according to Thomson Reuters. Revenue rose 11% to $2.78 billion, Scalper1 News
Scalper1 News